Freedom of Information request on the authorisation of Repevax ( FOI 21/1196)
Published 26 May 2022
© Crown copyright 2022
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-15-november-2021/freedom-of-information-request-on-the-authorisation-of-repevax-foi-211196
FOI 21/1196
19th November 2021
Dear,
Thank you for your email.
According to our records, Repevax is authorised in the UK to Sanofi Pasteur Europe (PL 46602/0005). It was authorised on 30-11-2016 by a Change of Authorisation Holder from PL 06745/0121. PL 06745/0121 was granted by an incoming mutual recognition procedure on 19-11-2002 (DE/H/0215/001/MR). Our records also state that Repevax is not currently marketed. We would advise that you contact Sanofi Pasteur Europe for further information as to why this is.
Kind Regards
MHRA Customer Service Centre
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU
Telephone 020 3080 6000